High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

Barbara Vannata; Idanna Innocenti; Francesco Autore; Federica Sora'; Patrizia Chiusolo; Giuseppe Leone; Simona Sica; Luca Laurenti

doi:10.1002/ajh.23349

High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

Barbara Vannata
, Idanna Innocenti
, Francesco Autore
, Federica Sora'
, Patrizia Chiusolo
, Giuseppe Leone
, Simona Sica
, Luca Laurenti^*

^*Corresponding author

Research output: Contribution to journal › Article

2 Citations (Scopus)

Abstract

Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody\r\nwith a high efficacy in fludarabine- and alemtuzumab-refractory B cell\r\nchronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage\r\nwith the addiction of high dose corticosteroids to the Ofa at standard dose in\r\nthis type of patients, obtaining an OR rate of 78%, have recently been published\r\nin the literature [3].

Original language	English
Pages (from-to)	N/A-N/A
Journal	American Journal of Hematology
Volume	87
Issue number	12
DOIs	https://doi.org/10.1002/ajh.23349
Publication status	Published - 2012

All Science Journal Classification (ASJC) codes

Hematology

Keywords

Chronic Lymphocytic Leukemia

Access to Document

10.1002/ajh.23349

Cite this

@article{07e964f2681b456291763b06fd3d3537,

title = "High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia",

abstract = "Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody\textbackslash{}r\textbackslash{}nwith a high efficacy in fludarabine- and alemtuzumab-refractory B cell\textbackslash{}r\textbackslash{}nchronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage\textbackslash{}r\textbackslash{}nwith the addiction of high dose corticosteroids to the Ofa at standard dose in\textbackslash{}r\textbackslash{}nthis type of patients, obtaining an OR rate of 78\%, have recently been published\textbackslash{}r\textbackslash{}nin the literature [3].",

keywords = "Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia",

author = "Barbara Vannata and Idanna Innocenti and Francesco Autore and Federica Sora' and Patrizia Chiusolo and Giuseppe Leone and Simona Sica and Luca Laurenti",

year = "2012",

doi = "10.1002/ajh.23349",

language = "English",

volume = "87",

pages = "N/A--N/A",

journal = "American Journal of Hematology",

issn = "1096-8652",

publisher = "John Wiley and Sons Inc.",

number = "12",

}

TY - JOUR

T1 - High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

AU - Vannata, Barbara

AU - Innocenti, Idanna

AU - Autore, Francesco

AU - Sora', Federica

AU - Chiusolo, Patrizia

AU - Leone, Giuseppe

AU - Sica, Simona

AU - Laurenti, Luca

PY - 2012

Y1 - 2012

N2 - Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody\r\nwith a high efficacy in fludarabine- and alemtuzumab-refractory B cell\r\nchronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage\r\nwith the addiction of high dose corticosteroids to the Ofa at standard dose in\r\nthis type of patients, obtaining an OR rate of 78%, have recently been published\r\nin the literature [3].

AB - Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody\r\nwith a high efficacy in fludarabine- and alemtuzumab-refractory B cell\r\nchronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage\r\nwith the addiction of high dose corticosteroids to the Ofa at standard dose in\r\nthis type of patients, obtaining an OR rate of 78%, have recently been published\r\nin the literature [3].

KW - Chronic Lymphocytic Leukemia

UR - https://publicatt.unicatt.it/handle/10807/40290

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84869214436&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84869214436&origin=inward

U2 - 10.1002/ajh.23349

DO - 10.1002/ajh.23349

M3 - Article

SN - 1096-8652

VL - 87

SP - N/A-N/A

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 12

ER -

High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this